Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tunitas Raises $10 Million from Two China Investors

publication date: Oct 1, 2015
Tunitas Therapeutics, a San Francisco based biopharmaceutical company, raised $10 million in a Series A venture financing co-led by two China investors, Ally Bridge Group and WuXi Ventures. As part of the transaction, David Nikodem of Ally Bridge Group, and Sophie Qiao of WuXi Ventures have joined the Tunitas board of directors. Tunitas will use the funds to advance its lead fusion protein candidate, epsi-gam, through its initial Phase I clinical trials and the initiation of Phase IIa studies. The funding will also be used to continue the development of Tunitas' pipeline of novel targeted vaccines for the treatment of specific allergies. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital